Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00172185 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome Who Completed Protocol CL0600-004 (NCT00081458)
A Phase 3 study, sponsored by Shire.
- Completed
- Registry status
- Phase 3
- Development phase
- 65
- Enrollment target
NCT00172185 is a Phase 3 study that has completed, run by Shire. The registered enrollment target is 65 participants.
The verdict
NCT00172185, a Phase 3 study, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 65 participants
- Enrollment target
Study Summary
The purpose of this clinical study is to evaluate the long-term safety and efficacy of daily administration of teduglutide.
Interventions
- DRUG teduglutide 0.05 mg/kg/d
- DRUG teduglutide 0.10 mg/kg/d
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2005-01-10 |
| Est. Completion | 2008-01-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00172185
The ClinicalTrials.gov registry entry for NCT00172185 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which teduglutide 0.05 mg/kg/d is the first listed.
NCT00172185 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00172185 about?
NCT00172185 is a clinical study titled "Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome Who Completed Protocol CL0600-004 (NCT00081458)". The purpose of this clinical study is to evaluate the long-term safety and efficacy of daily administration of teduglutide.
What is the current status of trial NCT00172185?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 65 participants. The study started on 2005-01-10. Estimated completion is 2008-01-24.
What interventions are being tested in trial NCT00172185?
The interventions under investigation include: teduglutide 0.05 mg/kg/d (DRUG), teduglutide 0.10 mg/kg/d (DRUG).
Who is sponsoring clinical trial NCT00172185?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.